3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
10
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Neoplasm Metastasis
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Healthy Participants
2
Uterine Cervical Neoplasms
1
Solid Tumour
1
Recurrence
1
Ovarian Neoplasms
1
Moderate Hepatic Impairment
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
1
Endometrial Neoplasms
1
Disease Progression
1
Advanced Solid Tumours
1
Advanced Solid Malignancy,
1
Advanced Solid Malignancy
1
Interventions
capivasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Solid Malignancy,
×
capivasertib
×
Clear all
NCT01895946
2016-05-25
OAK
AstraZeneca
Phase 1
Completed
33 enrolled
14 charts